Why am I more than exciting ? :
Guadecitabin is just an investigational compound (no current approved any where)
On the contrary Zantrene has FIC and BIC status of FTO inhibitor, it has enormous and tangible historical data with approximately 90 patients have been treated with Zantrene. (Especially including data of patients in France that were treated that stored in the French approval documentation and historical files.)
- Thousands of doses administered if you include patients treated historically with Zantrene via trials for solid tumours.
So RACE have strong data on safety and Zantrene had been approved before and being retested in the Clinic on HUMAN right NOW.
With "500 measures cut once.." of RAC 's philosophy, I am so looking forward to our progressive result of EMD AML trial starting later this year 2022 hopefully.
AIMO
Industry news, page-787
-
- There are more pages in this discussion • 1,068 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |